(Q51853676)

English

Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.

scientific article published on 26 March 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

1 reference

based on heuristic

inferred from title

major depressive disorder

1 reference

based on heuristic

inferred from title

author name string

Jian-Jun Ou

1

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Guang-Lei Xun

2

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Ren-Rong Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Le-Hua Li

4

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Mao-Sheng Fang

5

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Hong-Geng Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Shi-Ping Xie

7

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Jian-Guo Shi

8

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Bo Du

9

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Xue-Qin Yuan

10

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Jing-Ping Zhao

11

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

publication date

26 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

number of pages

8

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

213

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

2-3

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

639-646

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Discontinuation symptoms in depression and anxiety disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram therapy for major depression and anxiety disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram prevents relapse in older patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Superiority of escitalopram to paroxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram in the long-term treatment of major depressive disorder in elderly patients

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Efficacy of escitalopram in patients with severe depression: a pooled analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram: superior to citalopram or a chiral chimera?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram in the long-term treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1822-Y

21 January 2018

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of escitalopram and citalopram efficacy: A meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escitalopram in the treatment of major depressive disorder: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The preclinical observation that escitalopram possesses a faster time to onset of efficacy than citalopram

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escitalopram versus other antidepressive agents for depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20340011

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-010-1822-Y

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20340011

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51853676&oldid=2211273849"